Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage

Crit Care Med. 2005 Jun;33(6):1384-91. doi: 10.1097/01.ccm.0000166371.18066.5e.

Abstract

Objective: Acute respiratory distress syndrome is occasionally seen in newborn infants due to a severe inflammatory process in the lungs that affects capillary-alveolar permeability, epithelial integrity, and type I and II pneumocyte function. The aim of this study was to investigate the effect of a topically applied nuclear factor-kappaB inhibitor (IkappaB kinase-NF-kappaB essential modulator binding domain [IKK-NBD] peptide) on gas exchange, lung function, lung fluids, and inflammation in a piglet model of repeated airway lavage that is characterized by surfactant deficiency, lung edema, and an inflammatory response.

Design: Prospective, randomized, controlled animal study.

Setting: Research laboratory of a university children's hospital.

Subjects: A total of 24 anesthetized, mechanically ventilated newborn piglets.

Interventions: Repeated airway lavage was carried out until both the Pao2 decreased to approximately 40 mm Hg, while ventilating the piglets with an Fio2 of 0.6, and a peak inspiratory pressure of >/=18 cm H2O was needed to maintain tidal volume at 6 mL/kg. One group of piglets served as a control (n = 8), a second group (S, n = 8) received a porcine surfactant preparation (Curosurf), and a third group received IKK-NBD peptide admixed to surfactant (S+IN, n = 8).

Measurements and main results: After 6 hrs of mechanical ventilation after intervention, S+IN group piglets showed decreased extravascular lung water (S+IN vs. S, 20 +/- 3 vs. 28 +/- 10 mL/kg; p < .05) and a lesser protein content in the epithelial lining fluid (S+IN vs. S, 38 +/- 5 vs. 50 +/- 5 mg/L; p < .05). Functional residual capacity (S+IN vs. S, 16.7 +/- 6.3 vs. 12.2 +/- 4.3 mL/kg; p < .05), alveolar volume (S+IN vs. S, 5.4 +/- 1.8 vs. 4.6 +/- 1.5 mL/kg; p < .05), and lung mechanics were improved. Bronchoalveolar lavage showed a lesser percentage of polymorphonuclear leukocytes (S+IN vs. S, 70% +/- 6% vs. 82% +/- 3%; p < .01) and a reduction in the chemokine leukotriene B4 (S+IN vs. S, 2.0 +/- 0.6 vs. 3.5 +/- 1.4 pg/mL; p < .01).

Conclusions: A topically applied nuclear factor-kappaB inhibitor improves lung edema and lung volumes and reduces inflammation in this newborn piglet model of airway lavage.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Cell-Penetrating Peptides / pharmacology
  • Cell-Penetrating Peptides / therapeutic use*
  • Cytokines / metabolism
  • Extravascular Lung Water / metabolism
  • Humans
  • I-kappa B Kinase
  • Infant, Newborn
  • NF-kappa B / antagonists & inhibitors*
  • Neutrophils / metabolism
  • Protein Serine-Threonine Kinases / pharmacology
  • Protein Serine-Threonine Kinases / therapeutic use*
  • Pulmonary Edema / drug therapy*
  • Pulmonary Gas Exchange / drug effects
  • Pulmonary Surfactants / therapeutic use*
  • Random Allocation
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / pathology
  • Respiratory Mechanics / drug effects
  • Statistics, Nonparametric
  • Swine
  • Total Lung Capacity / drug effects

Substances

  • Cell-Penetrating Peptides
  • Cytokines
  • IKK NBD peptide
  • NF-kappa B
  • Pulmonary Surfactants
  • Protein Serine-Threonine Kinases
  • CHUK protein, human
  • I-kappa B Kinase
  • IKBKB protein, human
  • IKBKE protein, human